Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.
about
Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementClinical Phenotypes in Heart Failure With Preserved Ejection FractionMetabolic Syndrome and the LungWorld Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.Role of echocardiography in clinical hypertensionEmerging Metabolic Therapies in Pulmonary Arterial Hypertension.Kidney dysfunction in patients with pulmonary arterial hypertensionPoor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fractionPhenotypic spectrum of heart failure with preserved ejection fraction.Causes of pulmonary hypertension in the elderly.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease.Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fractionResponse to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factorsPredictors of diastolic-to-wedge gradient in patients evaluated for pulmonary hypertension.Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessonsPulmonary hypertension: types and treatments.Right heart dysfunction in heart failure with preserved ejection fractionCase series of 5 patients with end-stage renal disease with reversible dyspnea, heart failure, and pulmonary hypertension related to arteriovenous dialysis access.The WHO classification of pulmonary hypertension: A case-based imaging compendium.Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection FractionPrevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fractionHemodynamic responses to rapid saline loading: the impact of age, sex, and heart failureSIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionAdministration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.Pulmonary hypertension in Saudi Arabia: A single center experience.WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.Time Dependence of the Effect of Right Ventricular Dysfunction on Clinical Outcomes After Myocardial Infarction: Role of Pulmonary HypertensionHemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertensionHigh prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.Epidemiology of pulmonary hypertension in the elderly.Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study.Which prognostic factors should be used in pulmonary arterial hypertension in elderly patients?The other pulmonary hypertension: heart failure with preserved ejection fraction.Heart failure with preserved ejection fraction: a clinical dilemma.Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure.Management of pulmonary hypertension due to heart failure with preserved ejection fraction.Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease.Towards Precision in HF Pharmacotherapy.
P2860
Q26750994-2EA94D07-E07D-4213-B72A-50600D47A3BDQ28073079-88ED2067-FF8A-4F12-939B-8EA0654F42CEQ28384152-7BB99F03-5AE3-4363-B15A-588C85EB1FAEQ30248878-B5CB0C50-D5C1-474A-9479-3508352D8539Q30390785-A54043B3-F6D4-4E9F-A603-A08E2071737CQ33608219-C8B17288-53F7-4AA5-B1D3-2395DCCC6F0CQ33738621-D5C7C5BA-1755-448E-A58E-DBCB83A401D5Q33788474-079220F9-5D44-4180-B3D2-1BC9673F2571Q33827302-D95B0C33-5F2B-41B1-B557-AD4DFD556410Q33829641-A7F83829-C432-4EFA-9914-95FF957C1697Q33965866-6AFF0A0A-FF6F-40D0-BB85-D8EA2510B407Q34633271-67D644F5-D925-49DD-B7A0-55CF58AD79BFQ34782595-74D4BA7F-CE50-4476-BC70-89F46ACB703EQ35016971-EA43B250-3212-4070-BF5F-2EAA7BB7BDCDQ35139959-1111D38B-DA33-465D-BF96-1FC65913B619Q35139972-350FB343-1602-4397-BD8A-1208C8BF396FQ35588220-AF73C595-8F4C-4A9A-B858-4F6CA43610E4Q35665792-B8435CE2-5576-4B4C-8752-EE3D85FC4449Q35929731-4A4510A4-31F7-4B87-A9E3-279A343ECE50Q35954669-7FB4D6A7-D370-4081-8402-0E8E3EEC74BEQ36203267-6017030B-EDEE-46C1-AB92-8B1B351768A3Q36547195-815520E6-6C3E-4C51-8216-883E34690FAFQ36614556-6C50BC74-B722-4558-B38E-D2FDCB25747AQ36872140-57015041-7F0B-40D5-A2D3-A820E7FAF869Q36886438-6A8122B3-BAE4-454B-B010-4184FBEF29BFQ37073847-B611EDCE-C05E-47F9-8047-830152C59975Q37094698-24E8DCF4-534D-4D8E-8E31-1DF7B9E84367Q37240741-1A82C308-2E47-4D73-882E-5CBD548131EBQ37248323-4A0A255B-C1A5-4CB1-BE81-1A66EFE8971EQ37602928-AC458AA2-71AC-4FA8-94BD-BAD3097D773AQ37670921-F9506D80-B121-4E34-A8B9-C6D97D276FD2Q37670927-D35FA21B-248C-4A5A-BDC8-5E4AD0B2B721Q37670930-CC24BBD2-1144-4C7E-9854-1693BD17F5ECQ37898743-92E7EEC8-7C18-4DAF-9E6D-33EC14C64D79Q38195149-411DA8C5-B6A3-4A08-98F0-983750B6804FQ38241108-7E2CE053-184A-4E0A-AAE0-A19EE5798791Q38260650-874DACE0-71EA-4522-BF49-C0B255D1998AQ38261197-DEC4E20C-0B40-498A-BC87-D24B22CF2BA1Q38737284-AB551971-AFB2-462B-BCCE-44DADF26E75DQ38758440-E4877429-9050-4A52-A255-DC6AB782C991
P2860
Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Clinical characteristics of pu ...... d preserved ejection fraction.
@en
Clinical characteristics of pu ...... d preserved ejection fraction.
@nl
type
label
Clinical characteristics of pu ...... d preserved ejection fraction.
@en
Clinical characteristics of pu ...... d preserved ejection fraction.
@nl
prefLabel
Clinical characteristics of pu ...... d preserved ejection fraction.
@en
Clinical characteristics of pu ...... d preserved ejection fraction.
@nl
P2093
P1476
Clinical characteristics of pu ...... d preserved ejection fraction.
@en
P2093
Ajay Vallakati
Brett Collander
Mardi Gomberg-Maitland
Pranavkumar Shroff
Sanjiv J Shah
Stuart Rich
P304
P356
10.1161/CIRCHEARTFAILURE.110.958801
P577
2011-03-16T00:00:00Z